Penumbra, Inc
A medical device company that builds tools to remove blood clots from the brain and blood vessels, helping treat strokes and other vascular emergencies. Its Penumbra System and Indigo System use vacuum suction to pull clots out through thin catheters. Founded in 2004 by a neurointerventionalist and a former real estate lawyer who were college roommates, the name comes from the Latin for "almost shadow" — the lighter edge of a shadow, and the term for brain tissue around a stroke that is damaged but not yet lost.
Sold 2.4K
Sold 100
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Elsesser AdamCEO, Director · 1 transaction | +13.9% | 865.5K | — | — | — |
| Roberts JohannaEVP, Gen. Counsel & Secretary · 1 transaction | -0.3% | 67.3K | — | — | — |
| Shiu LambertChief Accounting Officer · 1 transaction | -0.4% | 39.6K | — | — | — |
| Narayan ShruthiPresident · 1 transaction | -0.4% | 30.8K | — | — | — |
| Yuen MaggieChief Financial Officer · 2 transactions | -12.6% | 18.2K | — | — | 2.4K |
| Grewal HarpreetDirector · 1 transaction | -1.1% | 8.7K | — | — | 100 |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -2.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.